Skip to main content

FDA Approvals

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO, Oncology

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

Trodelvy Receives New Indication for Advanced Urothelial Cancer

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

Page 12 of 53
Results 111 - 120 of 527